Skip to main content
HESTERBIO · Health Care · 2026-08-21

Hester Biosciences Ltd

5.4★ FairSolid +5.8Stage 2 · wk 11In scan: Pullback Hunter · Prop ScanMARKET: BULL RISING · 2026-08-21
₹2,367.8
-1.88% today
₹2,014 Cr · Small cap
About this companyHealth Care· Biotechnology
Expand ▾

Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. It operates through the Poultry Healthcare and Animal Healthcare segments. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal, fowl pox, marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis. It also offers vaccines for peste des petits ruminants, goat pox, brucella abortus, lumpy skin disease, contagious bovine pleuropneumonia, and contagious caprine pleuropneumonia for cattle, buffalo, sheep, and goats; and diagnostic services. In addition, the company provides animal healthcare products, such as biosecurity solutions, therapeutic treatment, herbal supplements, homeopathic remedies, and feed supplements. Further, it offers various pet care products, including gut health solutions, NSAIDs, joint care formulations, parasiticides, grooming aids, and anti-infective formulations; and healthcare products, such as immune boosters, gut health enhancers, vitamins, minerals and specialty feed supplements, and various formulations for critical needs comprising disease prevention, growth, and nutritional balance. Additionally, the company provides sero-profiling kits, diagnostic labs for poultry flocks, and mastitis control programs for cattle; and manufactures and trades in goods. Hester Biosciences Limited was incorporated in 1987 and is headquartered in Mehsana, India.

Visit company website →
P/E (TTM)
29.5
Forward —
Earnings Growth (YoY)
+968.7%
Revenue +38.2%
ROE
+16.6%
Profit margin +16.7%
Dividend Yield
0.32%
P/B 4.7
vs 52W High
-7.0%
₹1,259.1 lo₹2,545 hi
7.0% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 11
1w13w26w
Week 11 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
33.1%
200 DMA: ₹1,778.7 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.15x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
MA20 flat · -0.0% vs MA50 +10.1%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
This stock ranks #36 of 84 Stage 2 stocks in Health Care by RS.
Industry
Biotechnology
↓ Peaking
Stage 2%
57.1%
20d Δ
-14.3pp
1M return
+2.4%
3M return
+6.5%
Industry Stage-2 % · last 20 days
Ranks #2 of 4 Stage 2 stocks in this industry. Top tier.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-26 → 2026-08-21
S4 29w
S2 18w
S4 14w
S1 16w
S4 23w
2023-05-262026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 11w → S1 8w → S4 29w → S1 4w → S2 18w → S3 9w → S2 8w → S3 2w → S4 14w → S1 16w → S2 5w → S3 5w → S4 23w → S1 5w → S2 10w current
Total tracked: 168 weeks across 15 stage runs.
1M
+0.1%
3M
+26.3%
6M
+50.8%
YTD
+49.2%
1Y
+21.7%
Scan Membership
Pullback Hunter
Latest: 2026-08-21
Prop Scan
Latest: 2026-08-21
60 appearances in last 60 days. First seen: 2026-07-06.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S2
Wk 11 · Vol x
2026-08-20S2
Wk 10 · Vol x
2026-08-19S2
Wk 10 · Vol x
2026-08-18S2
Wk 10 · Vol x
2026-08-17S2
Wk 10 · Vol x
2026-08-14S2
Wk 10 · Vol x
2026-08-13S2
Wk 9 · Vol x
2026-08-12S2
Wk 9 · Vol x
2026-08-11S2
Wk 9 · Vol x
2026-08-10S2
Wk 9 · Vol x
2026-08-07S2
Wk 9 · Vol x
2026-08-06S2
Wk 8 · Vol x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹2,321.2
200 DMA
₹1,778.7
52W High
₹2,545
52W Low
₹1,259.1
5D Low
₹2,367.8
Resistance levels (recent highs)
20d High
₹2,528.4
60d High
₹2,545
120d High
₹2,545
250d High
₹2,545
Next resistance
+6.8%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.